Libtayo Gains Approval for First-Line NSCLC With Chemotherapy

 
• By Jessica Merrill
  
lung cancer
Regeneron's Libtayo added a new lung cancer indication • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip